© 2003 by European Society of Cardiology
Copyright © 2003, European Society of Cardiology
Impact of chymase inhibitor on cardiac function and survival after myocardial infarction
aDepartment of Pharmacology, Osaka Medical College, 2–7 Daigaku-machi, Takatsuki City, Osaka 569-8686, Japan
bResearch and Development Division, Nippon Kayaku Co., Ltd., Kita-ku, Tokyo 115-8588, Japan
*Corresponding author. Tel.: +81-72-684-6418; fax: +81-72-684-6518. Email address: pha012{at}art.osaka-med.ac.jp
Objectives: Recent studies have demonstrated that hamsters, like humans, possess both angiotensin converting enzyme (ACE)- and chymase-dependent angiotensin (Ang) II-forming pathways in cardiovascular tissues. We recently found that, after myocardial infarction (MI) in hamsters, cardiac chymase was significantly activated. In order to determine whether suppression of cardiac chymase activity could provide prognostic benefit after MI, we examined the effects of NK3201, a novel, orally active and specific chymase inhibitor, on cardiac function and survival during the acute phase of MI in hamsters. Methods: Two hundred and ten male Syrian hamsters were used in the present study. The left coronary artery of each hamster was ligated to induce MI. NK3201 at a dose of 30 mg/kg per day was administered orally by gastric gavage, starting either 3 days before or 1 day after MI. Results: ACE and chymase activities were significantly increased in the infarcted left ventricle 3 days after MI. NK3201 treatment starting 3 days before MI significantly inhibited the increase in cardiac chymase activity, while it did not affect ACE activity either in plasma or in heart 3 days after MI. A significant improvement in cardiac function was observed 3 and 14 days after MI in the group receiving NK3201. Compared with vehicle treatment, NK3201 treatment initiated either 3 days before or 1 day after MI significantly reduced the mortality rate during the 14 days of observation following MI. Conclusions: These findings indicate that cardiac chymase plays an important role after MI and this finding may provide a novel therapeutic target in post-MI treatment.
KEYWORDS Angiotensin; Heart failure; Infarction; Ischemia; Ventricular function
Time for primary review 44 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W. W. Raymond, S. Su, A. Makarova, T. M. Wilson, M. C. Carter, D. D. Metcalfe, and G. H. Caughey {alpha}2-Macroglobulin Capture Allows Detection of Mast Cell Chymase in Serum and Creates a Reservoir of Angiotensin II-Generating Activity J. Immunol., May 1, 2009; 182(9): 5770 - 5777. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Femia, K. P. Maresca, S. M. Hillier, C. N. Zimmerman, J. L. Joyal, J. A. Barrett, O. Aras, V. Dilsizian, W. C. Eckelman, and J. W. Babich Synthesis and Evaluation of a Series of 99mTc(CO)3+ Lisinopril Complexes for In Vivo Imaging of Angiotensin-Converting Enzyme Expression J. Nucl. Med., June 1, 2008; 49(6): 970 - 977. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Jin, H. Ueda, S. Takai, Y. Okamoto, M. Muramatsu, M. Sakaguchi, N. Shibahara, Y. Katsuoka, and M. Miyazaki Effect of Chymase Inhibition on the Arteriovenous Fistula Stenosis in Dogs J. Am. Soc. Nephrol., April 1, 2005; 16(4): 1024 - 1034. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Tsunemi, S. Takai, M. Nishimoto, D. Jin, M. Sakaguchi, M. Muramatsu, A. Yuda, S. Sasaki, and M. Miyazaki A Specific Chymase Inhibitor, 2-(5-Formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[{3,4-dioxo-1-phenyl-7-(2-pyridyloxy)}-2-heptyl]acetamide (NK3201), Suppresses Development of Abdominal Aortic Aneurysm in Hamsters J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 879 - 883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Jin, S. Takai, M. Sakaguchi, Y. Okamoto, M. Muramatsu, and M. Miyazaki An Antiarrhythmic Effect of a Chymase Inhibitor after Myocardial Infarction J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 490 - 497. [Abstract] [Full Text] [PDF]
|
|